Month: May 2017

  • Home
  • >
  • Archive for May, 2017
coll2.jpg

CollPlant Signs New Exclusive Distribution Agreement in Turkey for Vergenix®FG Wound Treatment

Posted On May 23, 2017 By OrthoSpineNews In Biologics, Top Stories /  

NES ZIONA, Israel, May 22, 2017 /PRNewswire/ — CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human “rhCollagen”) technology for tissue repair products announced that the Company has signed a new, exclusive distributor agreement in Turkey to market Vergenix®FG, for the treatment of chronic wounds. The one year agreement includes a two-year extension option. The market potential for the treatment of chronic wounds in Turkey is estimated at in excess of 400,000 procedures annually.

Yehiel Tal, Chief Executive Officer of CollPlant, noted, “We have received excellent feedback from opinion leaders in Europe who have been using the product, and the signing of the agreement with the Turkish distributor represents a further layer in the implementation of the Company’s sales strategy on the continent. Our objective is to build up the sales infrastructure for Vergenix®FG through distributors in various, key territories.”

Below is a link to a video review by Professor Alberto Piaggesi, M.D., Director of the Diabetic Foot Section of the Pisa University Hospital, Italy and a member of the Council of the European Wound Management Association (EWMA). Dr. Piaggesi, who uses Vergenix®FG to treat patients with hard to heal chronic wounds, describes the product’s advantages and its success in closing wounds. (Warning: the video includes pictures from treatment that some viewers might find distressing).

CollPlant Vergenix FG – Prop. Alberto Piaggesi – Youtube

About Vergenix®FG

Vergenix®FG is an injectable gel compound based on the Company’s human collagen, which has shown to treat chronic wounds and operation-based incisions, including diabetic foot ulcer. The gel is injected directly into the wound, thereby filling it and facilitating a healing process through to complete wound closure, without any side effects such as infections or allergies which may occur with other treatment options.

About CollPlant

CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company’s cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant’s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company’s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix®STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix®FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant’s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.

For more information about CollPlant, visit http://www.collplant.com

Contact at CollPlant:                                   

Eran Rotem
Chief Financial Officer
Tel: + 972-73-2325600/612
Email: Eran@collplant.com

Contact at Rx Communications Group, LLC:

Paula Schwartz (for US Investors)
Managing Director
Tel: 917-322-2216
Email: pschwartz@rxir.com

SOURCE CollPlant

Related Links

http://www.collplant.com

Read More
headquarters.jpg

Organogenesis Closes on a $20 Million Facility from Eastward Capital Partners

Posted On May 23, 2017 By OrthoSpineNews In Biologics, Financial, Top Stories /  

CANTON, Mass., May 22, 2017 /PRNewswire/ — Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, today closed a $20 million financing facility with Eastward Capital Partners, a leading provider of venture debt and equity financing to technology companies.

“We were fortunate to have several choices in a financing partner as we continue to build our balance sheet and our product portfolio to provide the most advanced wound care and surgical biologics solutions to our customers,” said Tim Cunningham, Chief Financial Officer of Organogenesis Inc. “We chose Eastward Capital Partners given their impeccable credentials and stellar reputation, which aligns well with Organogenesis’ core values.  Additionally, Eastward Capital Partners has decades of experience financing health technology companies and understands the value our products bring to clinicians and patients.”

“Eastward Capital Partners is committed to partnering with technology-forward companies who are leaders in their industry segments,” said Eastward Partner’s Tim O’Loughlin. “We are excited to partner with Organogenesis to provide the capital to support their growth plans.”

About Organogenesis Inc.
Originally founded as a spin-off from technology developed at MIT in 1985, Massachusetts-based Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products for advanced wound care, orthopedics, and spine. Organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

About Eastward Capital Partners
Eastward has provided private debt to leading companies in the Information Technology, Communications, New Media and Healthcare sectors since 1994.  As one of the oldest and most respected investors in the market, Eastward has a long history of working with companies to craft funding solutions which allow companies to reach their full potential.  www.eastwardcp.com

CONTACT:
Angelyn Lowe
(781) 830-2353
alowe@organo.com

SOURCE Organogenesis Inc.

Related Links

http://organogenesis.com/

Read More
NuVasive-Headquarters.jpg

NuVasive Announces Educational Initiatives In Support Of Spine’s Fastest Growing Spinal Deformity Portfolio

Posted On May 23, 2017 By OrthoSpineNews In Spine /  

SAN DIEGO, May 22, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company’s increased investment and support of adult and pediatric deformity research, education, and awareness initiatives throughout 2017.

NuVasive increased its focus on the $2.5 billion deformity market in May 2015 with the launch of its Integrated Global Alignment® (iGA®) platform and RELINE® posterior fixation system. In February 2016, NuVasive expanded its footprint into the early onset scoliosis market with the addition of its industry-leading MAGEC® system, which utilizes innovative magnetic technology within adjustable growing rods. Today, NuVasive has the fastest growing spinal deformity portfolio and is expanding its support of key programs to drive improved clinical and economic outcomes. NuVasive recently launched the ‘Embracing the Journey Together‘ program, which includes pediatric spinal deformity research, education and spinal deformity event support, supporting leading surgeons as they educate surgeons around the world.

“At NuVasive, we remain laser-focused on transforming the lives of patients through disruptive innovation and support of clinical education and research,” said Greg Lucier, NuVasive chairman and chief executive officer. “We’ve made tremendous gains in adult and pediatric spinal deformity innovation, with the versatile RELINE portfolio and MAGEC system. With the upcoming launch of the RELINE Small Stature system available this summer, I’m confident in our ability to outpace the market. We’re proud NuVasive has taken the lead in supporting key global initiatives designed to help improve the lives of patients around the world.”

Part of the Company’s investment into pediatric spinal deformity care includes funding research and patient initiatives, such as the Harms Study Group and its Setting Scoliosis Straight Foundation, as the exclusive sponsor of the Power Over Scoliosis event. NuVasive is also providing research funding for the Children’s Spine Study Group and the Growing Spine Study Group.

NuVasive was a key sponsor of EPOSNA 2017, the combined meeting of EPOS and POSNA, held earlier this month in Barcelona, Spain. In July, NuVasive is the leading sponsor of IMAST 2017, the International Meeting on Advanced Spine Techniques hosted by the Scoliosis Research Society. The Company is also the leading sponsor of ICEOS, the International Congress of Early-onset Scoliosis, in November.

The Company also announced the launch of a monthly podcast series, MAGEC Matters, featuring interviews with leading surgeons in pediatric deformity discussing tips for the treatment of early onset scoliosis, which is now available on iTunes, SoundCloud and other leading podcast platforms.

Other events supported by NuVasive throughout 2017 include:

  • Setting Scoliosis Straight: Patient & Family Power over Scoliosis Educational Event
    June 2-3, 2017; Miami
  • Shriners Hospital for Children – Chicago “Early Onset Scoliosis and Management Strategies” Meeting
    June 9, 2017; Chicago
  • International Meeting on Advanced Spine Techniques (IMAST)
    July 12-15, 2017; Cape Town, South Africa
  • Scoliosis Research Society (SRS)
    Sept. 6-9, 2017; Philadelphia
  • Pediatric Orthopedic Surgical Techniques Lab (POST)
    Sept. 29-30, 2017; Memphis, Tenn.
  • International Congress of Early-onset Scoliosis (ICEOS)
    Nov. 16-17; 2017, San Diego
  • 2017 MAGEC Users Meeting
    Nov. 17-18, 2017; San Diego
  • International Pediatric Orthopaedic Symposium (IPOS)
    Nov. 28-Dec 2, 2017; Orlando, Fla.
  • Spina Bifida Association Walk-n-Roll Events
    Various U.S. cities throughout 2017

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA®platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Read More
Forbes-generic-logo-500x500-1.png

Forbes Names The DeAngelis Group Among the Top 250 Best Executive Recruiting Firms in 2017

Posted On May 19, 2017 By OrthoSpineNews In Recon, Spine /  

SCOTTSDALE, ARIZONA (PRWEB) MAY 19, 2017

The De Angelis Group, the largest search firm dedicated solely to the orthopedic industry was named amongst the top 250 “Best Executive Recruiting Firms” listed by Forbes for 2017. The recent article was published on http://www.forbes.com on May 3, 2017, written by Jeff Kauflin.

Forbes worked with analytics firm Statista to compile a list of 4,000 executive recruiting companies. They then asked thousands of recruiters, employees who have worked with recruiting companies and H.R. managers to take an online survey, and recommend up to 10 recruiting firms (excluding their own). With over 20,000 recommendations, each company was then ranked by the highest number of recommendations.

The De Angelis Group is proud to have been named on the 2017 Forbes list and looks forward to continually working hard to bring value to the orthopedic industry. The De Angelis Group’s Managing Partner, Drue De Angelis said after receiving the news “It is an honor to be recognized for this distinction but what truly compels us is helping drive enterprise value for the companies and investors who entrust us with their most critical executive hires.”
_____

About The De Angelis Group

Founded in 2000 with one thing in mind; driving enterprise value for Orthopedic Start-up companies. The DeAngelis Group works with many of the most innovative and exciting new companies in the early stages of development to build a Talented Leadership Team.Whether your company is new to the space or you require a turn-around, our consultants first gain a solid grasp of the deliverables and the specific experience that the leader will require and then conduct the search effectively and timely.  Our network in Orthopedics is vast and qualitative. We have developed algorithms to evaluate who best fits in the start-up environment and who can develop and execute a strategic plan achieving sustainable growth.

Visit The De Angelis Group’s website 

Read More
240_main.jpg

FDA Clears Iovera Cold Treatment Device for Knee OA Pain

Posted On May 19, 2017 By OrthoSpineNews In Regulatory, Top Stories /  

Megan Brooks, Medscape – May 18, 2017

The US Food and Drug Administration (FDA) has cleared the iovera device, from Myoscience, Inc, for the relief of pain and symptoms associated with knee osteoarthritis (OA) for up to 90 days. Myoscience is located in Fremont, California.

“The iovera technology is a nonopioid and nonsystemic treatment for blocking pain signals from peripheral nerves,” the company said in a news release announcing FDA 51(k) clearance of the device.

The device uses the body’s natural response to cold to treat peripheral nerves. It consists of a hand piece equipped with a nitrous oxide cartridge and three closely spaced 27-gauge closed-end needle tips. The nitrous oxide flows from the cartridge to the needle tips, creating a highly localized cold zone. The effect is transient and provides pain relief until the nerve regenerates and its sensory function is restored.

“The iovera technology has the potential to change the current paradigm of pain management for osteoarthritis. The patients that I have treated with this technology have experienced immediate and long-lasting pain relief and are grateful to have an option that is nonnarcotic and nonsystemic,” Vinod Dasa, MD, member of the Myoscience medical advisory board, said in the release.

 

READ THE REST HERE

Read More
umsatz-2016-curasan-main_image.jpg

DGAP-News: Curasan starts dynamically into the new year

Posted On May 19, 2017 By OrthoSpineNews In Financial /  

Kleinostheim, 18 May 2017 – curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, has continued to grow dynamically at the start of the year. Gross sales increased by 15.9 percent to EUR 1.89 million (Q1 2016: EUR 1.62 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) improved by 3.4 percent (Q1 2016: -0.45 m EUR), while earnings before interest and taxes (EBIT) remained virtually unchanged at -0.45 million euros (Q1 2016: -0.45 m euros). However, due to lower interest expense, the net result rose slightly as well by 8.7 percent to -0.46 million euros (Q1 2016: -0.50 m euros).

The consideration of the sales performance according to regional aspects shows that the clear growth of almost all regions was dynamically supported. In Europe, sales rose by 10.6 percent to EUR 0.66 million, in MENA sales more than doubled, rising by 128.6 percent to EUR 0.26 million. In Asia, growth was 7.6 percent, with sales of a total of EUR 0.40 million, while the US markets increased by 7.7 percent to EUR 0.46 million.

Cash and cash equivalents decreased by 78.7 percent to EUR 0.21 million (31.12.16: 1.01 EUR) as of the balance sheet date, whereas trade receivables increased by 11.6 percent to 2.35 million Euro (31.12.16: 2.11 mEUR). At the same time, trade payables rose by 22.2 percent to EUR 1.05 million (31.12.16: 0.86 mEUR). Shareholders’ equity fell by 4.8 per cent to EUR 8.52 million, compared to EUR 8.95 million as of the end of 2016.

“We have shown a strong first quarter and our sales are growing across the board in all regions,” explains Michael Schlenk, CEO of curasan AG. “As projected, we will continue to invest heavily in marketing and registrations for this growth. Since the beginning of the second quarter and under the direction of the Finance Department by our new CFO, Christine Uekert, we are also taking a new approach in terms of our receivables management as well as the working capital and achieving good success here.” In addition, the company announced, with the publication of the 2016 Annual Report, that a capital increase would be implemented in the current financial year. “Our dynamic and sustainable growth is well recognized by institutional investors as well as strategic ones. A good basis for a further growth financing”, Schlenk adds.

Further details on the quarterly figures published today as well as current developments in the second quarter will be discussed by the CEO today at 2.00 pm in the course of an open telephone conference for analysts, qualified investors and journalists. You can register by e-mail via the Investor Relations and Corporate Communications departments (IR@curasan.com).

The complete report on the first quarter of 2017 has been made available by curasan on the Company’s website at the following link:

www.curasan.de/investoren/publikationen/finanzberichte

Contact curasan AG:
Ingo Middelmenne
Head of Investor Relations
+49 6027 40 900-45
+49 174 90 911 90

ingo.middelmenne@curasan.com

Andrea Weidner
Head of Corporate Communications
+49 6027 40 900-51
andrea.weidner@curasan.com

About curasan AG:

curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan’s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

18.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de
Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
ISIN: DE0005494538
WKN: 549453
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service
Read More
nanofuse-bioactive-dbm.png

Florida Institute Funds Alachua-based Amend Surgical

Posted On May 19, 2017 By OrthoSpineNews In Biologics, Financial, Top Stories /  

GAINESVILLE, Fla. and BOCA RATON, Fla., May 18, 2017 /PRNewswire-USNewswire/ — The Florida Institute for the Commercialization of Public Research (the Florida Institute) announced today that it has finalized a funding agreement with Amend Surgical, an Alachua-based medical device company with newly licensed technology developed at the University of Florida. The Florida Institute supports new company development and expansion based on publicly-funded research, and bridges early funding gaps for companies licensing technology out of Florida-based universities and research institutions.

Amend Surgical is a specialty medical device company focused on enhancing the healing and regenerative capacity of bone grafts, including allograft, xenograft tissues and synthetic materials. The company’s pipeline includes novel, osteoinductive bone extracts, and will expand in the future to disruptive products based on discovery and development of novel therapeutic additives with tissue-specific regenerative characteristics.

“We are committed to advancing the science of orthobiologics by improving the healing capacity of bone grafts.  The new funding agreement with the Florida Institute will allow Amend to rapidly expand our research and commercialization efforts on Biomimetic Bone which was licensed from the University of Florida in March 2017,” said Robby Lane, Chief Executive Officer of Amend Surgical.

“Amend Surgical provides surgeons and their patients access to innovative bone grafting options,” said Jackson Streeter, MD, Florida Institute Chief Executive Officer. “By developing and advancing bone grafts and other orthobiologics with enhanced regenerative capacity, surgery patients can identify, with guidance from their physicians, new options that can help them achieve the best possible surgical outcomes.”

About the Florida Institute

Formed by the Florida Legislature in 2007, the Florida Institute for the Commercialization of Public Research is a non-profit organization that works collaboratively with the technology licensing and commercialization offices of Florida’s state universities and private research institutions to leverage a $2.5B+ research base and form investable companies that create clean jobs in new industries that are driving the global economy. With funding from the State of Florida through the Department of Economic Opportunity, and through the generosity of mentors, advisors and donors, the Florida Institute provides company building services, and seed funding through the Florida Technology Seed Capital Fund, to promising Florida startups. Sixty-nine companies have been funded to date, and the Florida Institute’s economic impact through June 30, 2016 in the State of Florida was $630 million.

About Amend Surgical

Amend Surgical is a product development company offering differentiated biologic solutions for surgeons, medical device manufacturers and distributors globally.  Amend is targeting the bone graft substitute market with licensed, patented, technology and is focused on spine, orthopedic and dental indications.  The R&D pipeline includes products loaded with antibiotics and natural bone morphogenic proteins. Additionally, Amend is commercializing a novel Biomimetic Bone technology licensed from the University of Florida that offers the hope for a synthetic graft with load bearing capability and osteostimulative properties.  Amend currently manufactures and distributes the only demineralized bone-bioactive glass combination product approved by the FDA. NanoFUSE® Bioactive Matrix uniquely combines the osteoinductive capabilities of demineralized allograft bone with the osteostimulative properties of 45S5 bioactive glass.

CONTACT:
Jane Teague
Chief Operating Officer
Institute for the Commercialization of Public Research
561-368-8889
jane.teague@florida-institute.com

 

SOURCE Florida Institute for the Commercialization of Public Research

Related Links

http://www.florida-institute.com

Read More
medtec_rosa.png

Zimmer Biomet licenses Intellectual Property from Bonutti Research Inc.

Posted On May 19, 2017 By OrthoSpineNews In Robotics, Top Stories /  

EFFINGHAM, ILLINOIS (PRWEB) MAY 18, 2017

Effingham, Illinois – May 18, 2017 – Bonutti Research Inc. and Zimmer Biomet have entered into a license agreement for Zimmer Biomet’s use of two patent families created by Dr. Peter Bonutti. U.S. Patent No. 9,301,845 adds to the strength of the innovative knee systems, Persona® The Personalized Knee System and the NexGen® Complete Knee Solution. U.S. Patent Nos. 9,269,987 and 9,585,725 support the development of the Rosa® robotic total knee application currently underway at Zimmer Biomet.

About Bonutti Research (BRI)

Founded by Peter Bonutti, MD in 1989, BRI is a medical device incubator with over 550 patents and patent applications involving diagnostics, surgical robotics, minimal invasive surgery, soft tissue fixation, and hip and knee arthroplasty. BRI has entered into over 740 licenses in numerous medical and surgical fields. Bonutti Research is a device incubator with in-house design, engineering, regulatory, manufacturing, and intellectual property teams.  Learn more about innovations from BRI at bonuttiresearch.com

Contact:
Lucas Wenthe
LWenthe(at)bonuttitechnologies(dot)com
(217) 342-3412 x5111

Read More
First_ViscoelasticDisc_WEB-1.jpg

First AxioMed Viscoelastic Total Disc Replacement Implanted in Sydney, Australia

Posted On May 18, 2017 By OrthoSpineNews In Spine /  

MALDEN, MASS. (PRWEB) MAY 18, 2017

Dr. Ralph Mobbs of the Neuro Spine Clinic completed the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old male patient suffering from a degenerative cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing surgery.

The AxioMed viscoelastic disc is a next-generation disc replacement that restores natural disc height, lordosis, stability and motion in the human spine. AxioMed was approved in 2016 to market and sell their viscoelastic cervical and lumbar Freedom total disc replacements in Australia by the Therapeutic Goods Administration.

Dr. Ralph Mobbs spoke to the advantages of the AxioMed cervical disc after the operation, stating, “The Freedom Cervical Disc is a new and innovative treatment that I’ve been eager to use. I found the prosthesis matched the patient’s anatomy well, restored disc height and fit very well within the intervertebral space. The disc was easily placed with AxioMed’s simple and effective instrumentation. I believe in this viscoelastic technology and its benefits and I look forward to using the Freedom Cervical Disc to treat my patients in the future.”

AxioMed CEO Dr. Kingsley R. Chin explained how an experience like Dr. Mobbs’ aligns with AxioMed’s vision. “AxioMed believes it can replicate the success of total joint restoration in the spine with our innovative and advanced viscoelastic total disc replacements with a high degree of patient satisfaction,” he said.

Dr. Chin added, “With the addition of the lateral lumbar technique, we expect AxioMed to be the worldwide leader in disc replacement surgery.”

Dr. Mobbs currently practices neurosurgery with a special interest in minimally invasive and complex spine surgery.

About AxioMed
Founded in 2001, AxioMed began its journey of exhaustively proving the Freedom® Disc through clinical studies in the USA and Europe, research, development and testing. In 2014, KICVentures recognized the disc’s enormous potential and acquired the company into their healthcare portfolio. AxioMed owns an exclusive viscoelastic material license on its proprietary Freedom Disc technology.

Read More
599_main.jpg

Central Connecticut Neurosurgery and Spine is the First in Connecticut to Offer New Treatment Option for Chronic Pain

Posted On May 18, 2017 By OrthoSpineNews In Neuro, Spine, Top Stories /  

PLANO, TEXAS (PRWEB) MAY 17, 2017

Dr. Ahmed Khan is the first physician in Connecticut to implant Nuvectra’s Algovita® Spinal Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Algovita SCS System has been FDA approved as a treatment option for chronic intractable pain since late last year.

Chronic pain affects over 100 million Americans, according to the Institute of Medicine, more than diabetes, cancer, and heart disease combined. Chronic pain is difficult to treat, but one potential treatment option is spinal cord stimulation, or SCS. SCS works by masking or interrupting pain signals as they travel up the spinal cord to the brain. A small, rechargeable battery is implanted under the patient’s skin and connected to thin wires, called leads, which stimulate the nerves sending pain signals. The stimulation “overrides” the pain signals, and instead of feeling pain, patients may feel a tingling sensation known as paresthesia.

The Algovita SCS System is a new offering to the SCS market, featuring 24 current sources and the broadest overall set of parametric ranges offered for tonic SCS. This combination provides flexible coverage and expanded programming options for individualized patient therapy. Algovita also offers the industry’s only stretchable leads, which are designed to reduce the risk of lead fracture and migration. In addition, the system’s percutaneous leads feature up to 12 contacts for wide coverage of potential pain areas. The Algovita system was designed to be patient-centric and easy to use. The wireless Pocket Programmer fits discreetly in a hand, purse, or pocket and allows a patient to conveniently adjust their therapy on the go.

For more information about Nuvectra and the Algovita Spinal Cord Stimulation system, visit http://www.nuvectramed.com.

About Dr. Ahmed Khan

Dr. Ahmed Khan is a neurosurgeon in New Britain, Connecticut and is affiliated with Bristol Hospital. He received his medical degree from University of Connecticut School of Medicine and has been in practice for more than 20 years. He is one of 2 doctors at Bristol Hospital who specialize in Neurological Surgery.

About Nuvectra Corporation

NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at http://www.nuvectramed.com.

Read More

Oasis Surgical

16000 N. 80th St Suite E | Scottsdale | AZ | 85260
Phone: (623) 363-9881
Copyright 2018 - Oasis Surgical
All rights reserved.